Novavax ‘could use an army’ to get its coronavirus vaccine to market

Gaithersburg’s Novavax Inc. (NASDAQ: NVAX) has been in the spotlight since January for its work on a novel coronavirus vaccine, but it will need more support to advance the program at the necessary speed, its head of research said Monday. The Maryland biotech is now moving toward a phase 1 clinical trial after pulling in support from local players. Two months after it started, “we’re very clearly confident that we can make a vaccine,” said Dr. Gregory Glenn, its president of research and…